Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma

NCT01431209 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT01431209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01431209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma
Lead sponsor
University of Nebraska
Phase
Phase 2
Overall status
Completed
Start date
August 12, 2011
Completion date
May 26, 2021
Enrollment
71 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, recurrent mature t- and nk-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma